Skip to main content
. 2020 Nov 4;12(11):3251. doi: 10.3390/cancers12113251

Figure 4.

Figure 4

AE burden by treatment cycle, B(t), grouped by off-treatment reason and treatment arm for A091105. The AE burden of patients on sorafenib who went off treatment due to adverse events (dashed red line) was higher than the AE burden of patients on sorafenib who remained on treatment (solid red line) or those on placebo who went off for disease progression (dotted blue line).